Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Gibble, Allison
Gross, Alan
and
Huang, Angela
2015.
Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.
Antibiotics,
Vol. 4,
Issue. 4,
p.
653.
Ng, Tat Ming
Khong, Wendy X.
Harris, Patrick N. A.
De, Partha P.
Chow, Angela
Tambyah, Paul A.
Lye, David C.
and
Conly, John
2016.
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
PLOS ONE,
Vol. 11,
Issue. 4,
p.
e0153696.
Adler, Amos
Katz, David E.
and
Marchaim, Dror
2016.
The Continuing Plague of Extended-spectrum β-lactamase–producing Enterobacteriaceae Infections.
Infectious Disease Clinics of North America,
Vol. 30,
Issue. 2,
p.
347.
Arizpe, Andre
Reveles, Kelly R.
Patel, Shrina D.
and
Aitken, Samuel L.
2016.
Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.
Current Infectious Disease Reports,
Vol. 18,
Issue. 12,
Tamma, Seetha M.
Hsu, Alice J.
and
Tamma, Pranita D.
2016.
Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.
Pediatric Drugs,
Vol. 18,
Issue. 1,
p.
1.
Tamma, Pranita D.
and
Villegas, Maria Virginia
2017.
Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population.
Antimicrobial Agents and Chemotherapy,
Vol. 61,
Issue. 8,
Gudiol, C
Royo-Cebrecos, C
Tebe, C
Abdala, E
Akova, M
Álvarez, R
Maestro-de la Calle, G
Cano, A
Cervera, C
Clemente, W T
Martín-Dávila, P
Freifeld, A
Gómez, L
Gottlieb, T
Gurguí, M
Herrera, F
Manzur, A
Maschmeyer, G
Meije, Y
Montejo, M
Peghin, M
Rodríguez-Baño, J
Ruiz-Camps, I
Sukiennik, T C
and
Carratalà, J
2017.
Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producingEnterobacteriaceaein haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR).
BMJ Open,
Vol. 7,
Issue. 1,
p.
e013268.
Gudiol, Carlota
Royo-Cebrecos, Cristina
Abdala, Edson
Akova, Murat
Álvarez, Rocío
Maestro-de la Calle, Guillermo
Cano, Angela
Cervera, Carlos
Clemente, Wanessa T.
Martín-Dávila, Pilar
Freifeld, Alison
Gómez, Lucía
Gottlieb, Thomas
Gurguí, Mercè
Herrera, Fabián
Manzur, Adriana
Maschmeyer, Georg
Meije, Yolanda
Montejo, Miguel
Peghin, Maddalena
Rodríguez-Baño, Jesús
Ruiz-Camps, Isabel
Sukiennik, Teresa C.
Tebe, Cristian
and
Carratalà, Jordi
2017.
Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Antimicrobial Agents and Chemotherapy,
Vol. 61,
Issue. 8,
Ahn, Jin Young
Ann, Hea Won
Jeon, Yongduk
Ahn, Mi Young
Oh, Dong Hyun
Kim, Yong Chan
Kim, Eun Jin
Song, Je Eun
Jung, In Young
Kim, Moo Hyun
Jeong, Wooyoung
Ku, Nam Su
Jeong, Su Jin
Choi, Jun Yong
Yong, Dongeun
Song, Young Goo
and
Kim, June Myung
2017.
The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.
BMC Infectious Diseases,
Vol. 17,
Issue. 1,
Paterson, David L.
and
Doi, Yohei
2017.
Antimicrobial Drug Resistance.
p.
889.
Takesue, Yoshio
Kusachi, Shinya
Mikamo, Hiroshige
Sato, Junko
Watanabe, Akira
Kiyota, Hiroshi
Iwata, Satoshi
Kaku, Mitsuo
Hanaki, Hideaki
Sumiyama, Yoshinobu
Kitagawa, Yuko
Mizuguchi, Toru
Ambo, Yoshiyasu
Konosu, Masafumi
Ishibashi, Keiichiro
Matsuda, Akihisa
Hase, Kazuo
Harihara, Yasushi
Okabayashi, Koji
Seki, Shiko
Hara, Takuo
Matsui, Koshi
Matsuo, Yoichi
Kobayashi, Minako
Kubo, Shoji
Uchiyama, Kazuhisa
Shimizu, Junzo
Kawabata, Ryohei
Ohge, Hiroki
Akagi, Shinji
Oka, Masaaki
Wakatsuki, Toshiro
Suzuki, Katsunori
Okamoto, Kohji
and
Yanagihara, Katsunori
2017.
Antimicrobial susceptibility of pathogens isolated from surgical site infections in Japan: Comparison of data from nationwide surveillance studies conducted in 2010 and 2014–2015.
Journal of Infection and Chemotherapy,
Vol. 23,
Issue. 6,
p.
339.
Pilmis, Benoit
Jullien, Vincent
Tabah, Alexis
Zahar, Jean-Ralph
and
Brun-Buisson, Christian
2017.
Piperacillin–tazobactam as alternative to carbapenems for ICU patients.
Annals of Intensive Care,
Vol. 7,
Issue. 1,
Seo, Yu Bin
Lee, Jacob
Kim, Young Keun
Lee, Seung Soon
Lee, Jeong-a
Kim, Hyo Youl
Uh, Young
Kim, Han-Sung
and
Song, Wonkeun
2017.
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli
.
BMC Infectious Diseases,
Vol. 17,
Issue. 1,
Tamma, Pranita D.
and
Rodriguez-Baňo, Jesus
2017.
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
Clinical Infectious Diseases,
Vol. 64,
Issue. 7,
p.
972.
Yoon, Young Kyung
Kim, Jong Hun
Sohn, Jang Wook
Yang, Kyung Sook
and
Kim, Min Ja
2017.
Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
International Journal of Antimicrobial Agents,
Vol. 49,
Issue. 4,
p.
410.
Poulakou, Garyphallia
Siakallis, Georgios
and
Tsiodras, Sotirios
2018.
Abdominal Sepsis.
p.
265.
Pana, Zoi Dorothea
and
Zaoutis, Theoklis
2018.
Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?.
F1000Research,
Vol. 7,
Issue. ,
p.
1347.
Ko, J.-H.
Lee, N. R.
Joo, E.-J.
Moon, S.-y.
Choi, J.-K.
Park, D. A.
and
Peck, K. R.
2018.
Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
European Journal of Clinical Microbiology & Infectious Diseases,
Vol. 37,
Issue. 2,
p.
305.
Giacobbe, Daniele Roberto
Bassetti, Matteo
De Rosa, Francesco Giuseppe
Del Bono, Valerio
Grossi, Paolo Antonio
Menichetti, Francesco
Pea, Federico
Rossolini, Gian Maria
Tumbarello, Mario
Viale, Pierluigi
and
Viscoli, Claudio
2018.
Ceftolozane/tazobactam: place in therapy.
Expert Review of Anti-infective Therapy,
Vol. 16,
Issue. 4,
p.
307.
Islas-Muñoz, Beda
Volkow-Fernández, Patricia
Ibanes-Gutiérrez, Cynthia
Villamar-Ramírez, Alberto
Vilar-Compte, Diana
and
Cornejo-Juárez, Patricia
2018.
Bloodstream infections in cancer patients. Risk factors associated with mortality.
International Journal of Infectious Diseases,
Vol. 71,
Issue. ,
p.
59.